Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
280
Recruiting, any sponsor type, condition "large B-cell lymphoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting280
- Completed905
280 trials
Showing 1 to 25, recently updated first.
Ain Shams UniversityAcademic, hospital or other
NCT07057765 · 40 participants (planned) · Start May 5, 2025 · Primary completion Nov 2027
Drug: Observational Assessment of Standard R-CHOP Treatment · For: DLBCL - Diffuse Large B Cell Lymphoma; Markers of Inflammation
Sites: Cairo, Egypt
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05890352 · 227 participants (planned) · Start Sep 26, 2023 · Primary completion Dec 1, 2029
Drug: Lenalidomide; Tafasitamab and 2 more · For: Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements and 3 more
Sites: Tucson, Arizona; Beverly Hills, California; Duarte, California · 104 sites in all
University of WashingtonAcademic, hospital or other
NCT06784726 · 27 participants (planned) · Start Sep 4, 2025 · Primary completion Apr 10, 2028
Drug: Odronextamab; Chimeric Antigen Receptor T-Cell Therapy · For: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma and 9 more
Sites: Seattle, Washington
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruiting
National Cancer Institute (NCI)NIH
NCT05272384 · 32 participants (planned) · Start Nov 3, 2022 · Primary completion Jun 28, 2027
Drug: Decitabine and Cedazuridine; Nivolumab · For: Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma and 3 more
Sites: Birmingham, Alabama; Duarte, California; Sacramento, California · 9 sites in all
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT07892027 · 26 participants (planned) · Start Nov 10, 2026 · Primary completion May 1, 2028
Drug: Axicabtagene Ciloleucel; Brexucabtagene Autoleucel and 3 more · For: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma and 1 more
Sites: Ann Arbor, Michigan
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT07478848 · 14 participants (planned) · Start May 29, 2026 · Primary completion Jan 1, 2029
Drug: Vancomycin 125mg; CAR-T · For: Large B Cell Lymphoma; Non Hodgkin Lymphoma (NHL); Diffuse Large B Cell Lymphoma (DLBCL) and 2 more
Sites: Philadelphia, Pennsylvania; Salt Lake City, Utah
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruiting
National Cancer Institute (NCI)NIH
NCT04002947 · 132 participants (planned) · Start Aug 5, 2019 · Primary completion Oct 12, 2027
Drug: DA-EPOCH; Rituximab and 2 more · For: Non-Hodgkin's Lymphoma; Diffuse Large B-Cell Lymphoma; DLBCL and 1 more
Sites: Bethesda, Maryland
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06806033 · 130 participants (planned) · Start Mar 5, 2025 · Primary completion Jul 31, 2029
Drug: Obinutuzumab; Glofitamab and 2 more · For: Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Sites: Anchorage, Alaska; Clovis, California; Fullerton, California · 53 sites in all
Shanghai Tongji Hospital, Tongji University School of MedicineAcademic, hospital or other
NCT07934537 · 20 participants (planned) · Start Oct 30, 2025 · Primary completion Aug 31, 2028
Drug: chidamide+PD-1 inhibitor · For: Large B-Cell Lymphoma (LBCL); Lymphoma, Large B-Cell, Diffuse
Sites: Shanghai, China
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06890884 · 594 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 13, 2027
Drug: Zilovertamab vedotin; Rituximab and 7 more · For: Lymphoma, Large B-Cell, Diffuse
Sites: Mobile, Alabama; Chandler, Arizona; Glendale, Arizona · 148 sites in all
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07519772 · 280 participants (planned) · Start May 3, 2026 · Primary completion Jul 1, 2030
Drug: MK-1045 · For: Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Sites: Los Angeles, California; Denver, Colorado; Cleveland, Ohio · 56 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06717347 · 1,046 participants (planned) · Start Jan 27, 2025 · Primary completion Jul 2, 2029
Drug: Zilovertamab vedotin; Rituximab and 8 more · For: Diffuse Large B-Cell Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 289 sites in all
National Cancer Institute (NCI)NIH
NCT03223610 · 155 participants (planned) · Start Feb 9, 2018 · Primary completion Aug 12, 2027
Drug: Venetoclax; Ibrutinib and 3 more · For: Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma and 1 more
Sites: Bethesda, Maryland
Umoja BiopharmaIndustry
NCT07735533 · 274 participants (planned) · Start Nov 2026 · Primary completion Aug 2031
Drug: Rapamycin (sirolimus) · For: Lymphoma, B Cell; Lymphoma Non-Hodgkin; High Grade B Cell Lymphoma and 4 more
Sites: Irvine, California; Nashville, Tennessee
- A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLPivotal-lookingRecruiting
HutchmedIndustry
NCT07409428 · 240 participants (planned) · Start Mar 20, 2026 · Primary completion Apr 30, 2028
Drug: HMPL-760; HMPL-760 Placebo and 1 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Shanghai, China; Baoding, China; Beijing, China · 51 sites in all
National Cancer Institute (NCI)NIH
NCT06649812 · 120 participants (planned) · Start Oct 7, 2025 · Primary completion Sep 1, 2028
Drug: Ibrutinib; Lenalidomide and 3 more · For: High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type and 12 more
Sites: Tucson, Arizona; Los Angeles, California; Derby, Connecticut · 115 sites in all
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruiting
ModeX Therapeutics, An OPKO Health CompanyIndustry
NCT07249905 · 180 participants (planned) · Start Apr 13, 2026 · Primary completion Jan 2028
Drug: MDX2003 · For: Lymphoma; Waldenström Macroglobulinemia (WM); DLBCL - Diffuse Large B Cell Lymphoma and 5 more
Sites: Richmond, Australia; Nedlands, Australia; Haifa, Israel · 7 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07200375 · 300 participants (planned) · Start Sep 29, 2025 · Primary completion Sep 29, 2029
Drug: Glofitamab · For: Diffuse Large B-Cell Lymphoma
Sites: Langfang, China; Tianjin, China; Beijing, China · 22 sites in all
National Cancer Institute (NCI)NIH
NCT07649304 · 15 participants (planned) · Start Jul 5, 2027 · Primary completion Dec 1, 2028
Drug: Cyclophosphamide; Doxorubicin Hydrochloride and 4 more · For: AIDS-Related Diffuse Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements and 6 more
Sites: Rockville, Maryland
Vijendra SinghAcademic, hospital or other
NCT05852717 · 35 participants (planned) · Start Oct 31, 2023 · Primary completion Nov 24, 2027
Drug: GDP; Epcoritamab · For: Large Cell Lymphoma, Diffuse; Relapsed Cancer; Refractory Cancer
Sites: Indianapolis, Indiana; Detroit, Michigan; Dallas, Texas · 4 sites in all
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07101328 · 215 participants (planned) · Start May 28, 2026 · Primary completion Apr 2027
Drug: LY4152199 - IV · For: Lymphoma, Non-Hodgkin; B-cell Lymphoma; Lymphoma, Large B-Cell, Diffuse and 4 more
Sites: Duarte, California; Aurora, Colorado; Denver, Colorado · 51 sites in all
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT03125642 · 150 participants (planned) · Start Apr 20, 2017 · Primary completion Sep 30, 2027
Drug: Etoposide; BCNU and 4 more · For: Non-Hodgkin Lymphoma; Hodgkin Lymphoma
Sites: Minneapolis, Minnesota
Eli Lilly and CompanyEli Lilly (LLY)
NCT07226843 · 460 participants (planned) · Start Apr 17, 2026 · Primary completion Sep 2028
Drug: LY4584180; Rituximab · For: Lymphoma, Non-Hodgkin's; Lymphoma, Diffuse Large B-Cell; Follicular Lymphoma
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 46 sites in all
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06091865 · 904 participants (planned) · Start Dec 13, 2023 · Primary completion Mar 30, 2028
Drug: Odronextamab; Rituximab and 4 more · For: Diffuse Large B-cell Lymphoma (DLBCL)
Sites: Scottsdale, Arizona; Los Angeles, California; Orange, California · 195 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.